MACOM Technology Solutions Holdings, Inc., together with its subsidiaries, provides analog semiconductor solutions for use in wireless and wireline applications across the radio frequency (RF), microwave, millimeter wave…
Positioning political selling, disclosed 2026-09-29
Options put/call open interest 9.73, read 2026-11-02
Ethical passes the values gate
Price222.18 USD
Fair value223.42
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Distribution271.39-18.1% to today ✓Markup gives way to Distribution
2026-10-02Read Markup279.11-20.4% to today Distribution gives way to Markup after a 6% rise in 8 weeks
2026-08-06Read Distribution263.08-15.5% to today ✓Markup gives way to Distribution after a 31% slide in 5 weeks
2026-07-02Read Markup379.87-41.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
MACOM Technology Solutions Holdings Inc holds its Distribution at $222.18. The statistical read favours the sellers, held for 7 days.
As held on the ledger · 2026-11-02
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 7 days
Price at the screen
$222.18
Valuation
75.24 trailing · 27.79 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.76
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.58%
Below 33%
Interest-bearing debt is just 25.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
32.04%
Below 33%
Cash held in interest-bearing accounts and securities is 32.0% of assets, under the one-third limit.
Pass
Receivables
12.40%
Below 49%
Money owed to the company is 12.4% of assets, under the 49% limit.
Pass
Revenue purity
3.09%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
MACOM Technology Solutions clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-02. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MTSI's ethical verdict changes
Today MTSI passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-11-02 screen. The gold marker is the market price at the same screen. A 0.6% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +69% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $223.42, with a range of $223.42 to $256.93, dated to the 2026-11-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Paying a Premium for Semiconductor Cycles
Picture a foundry running flat out during the next wireless boom, only to idle when demand swings the other way. MACOM sits in that exact spot, yet the shares trade at a 14% premium to our fair value with no opportunity rating attached.
Revenue is growing 22% and the firm clears a 16% profit margin with 13% ROE and a narrow moat. Those figures look respectable, yet the 38.6 times forward earnings multiple already prices in strong optimism that leaves little room for the usual industry swings.
Because the business is cyclical, peak margins often coincide with peak multiples and create lasting value traps once orders slow. Analysts may cluster around a $400 target, but the gap between price and fair value keeps us on the sidelines despite an ethical pass.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MTSI trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Distribution$222.18-5.2%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Distribution$234.39+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Distribution$234.39+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$234.39-7.1%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$252.42-3.3%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$260.92+10.4%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Distribution$236.24-13.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. Since the last review it entered the Titan Ethical 500; its composite score rose.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 17.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398.
2026-10-14Markup$330.06+18.3%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 83% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398. Since the last review it its composite score eased.
2026-10-02Markup · changed$279.11+8.4%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 83% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 176%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (14 analysts) rates it none, with a mean price target of $398.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
